Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 37, Issue 9, 2006, Pages 825-829

  Sahebi, F ^a   Spielberger, R ^a   Kogut, N M ^a   Fung, H ^a   Falk, P M ^a   Parker, P ^a   Krishnan, A ^a   Rodriguez, R ^a   Nakamura, R ^a   Nademanee, A ^a   Popplewell, L ^a   Frankel, P ^a   Ruel, C ^a   Tin, R ^a   Ilieva, P ^a   Forman, S J ^a   Somlo, G ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplant; Maintenance; Multiple myeloma; Thalidomide

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ANOREXIA; APHASIA; ARTICLE; ASTHENIA; ATAXIA; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BODY WEIGHT DISORDER; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSLEXIA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

AGED; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SURVIVORS; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33646025265     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705339     Document Type: Article

References (19)

1. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results. Br J Haematol 1998; 102: 495-502.
2. Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
3. Davis F, Raje N, Hideshima T, Lentzsch S, Yong G, Tai Y et al. Thalidomide and immuno modulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
4. Gupta D, Treon SP, Shima Y, Hideshma T, Podark K, Tai Y et al. Adherence of multiple myeloma cells to bone marrow stromal cell upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001; 15: 1950-1961.
5. Weber D, Rankin K, Gavino M, Delsalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 34: 1565-1571.
7. Mahoney D, Molina A, Sahebi F, Stockerl-Goldstein K, Sandmaier B, Bensinger W et al. Allografting with non-myleloablative. Conditioning following cyotoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
8. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplant: Myeloma subcommittee of the EBMT. Br J Haematol 1998; 102: 1115-1123.
9. Stewart K, Chen C, Howson-Jan K, White D, Roy J, Kovacs M et al. Results of multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 24: 8170-8176.
10. Scarpace S, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A et al. Arterial thrombosis in four patients treated with thalidomide. Leukemia and Lymphoma 2005; 46: 239-242.
11. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al. Thalidomide and deep venous thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 2003; 4: 32-35.
12. Barlogie B, Desikan R, Eddelmon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
13. Neben K, Moehler T, Benner A, Egere G, Ho A, Goldschmidt H et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-3382.
14. Palumbo A, Bertola A, Falco P, Cavallo F, Giaccone L, Bringhen S et al. Efficacy of low dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-324.
15. Durie BG. Low-dose thalidomide in myeloma: Efficacy and biologic significance. Semin Oncol 2002; 29 (6 Suppl): 34-38.
16. Alexanian R, Weber D, Giralt S, Delasalle KL. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive therapy. Ann Oncol 2002; 13: 1116-1119.
17. Attal M, Harousseau HL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma. First analysis of prospective randomized study of IFM99-02. Blood 2004; 10 (abstract 535).
18. Tricot G, Rasmussen E, Anaissie E, Van Rhee F, Zangari M, Holling K et al. Total therapy 2 (TT 2) for multiple myeloma: Thalidomide effects superior complete response and event-free survival; similar overall survival linked to shorter post relapse survival. Blood 2005; 106 (abstract 423).
19. Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K, Johnson RL. Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. Blood 2005; 106 (abstract 641).